Alder BioPharmaceuticals announces exercise in full of underwriters’ option
Alder BioPharmaceuticals announced underwriters of its previously announced offering of 2.50% convertible senior notes due 2025 have exercised in full their option to purchase up to an additional $37.5 million aggregate amount for a total offering of $287.5 million in aggregate principal amount. February 13, 2018